Clinical Trial Update: Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial evaluating intravitreal bevacizumab for central serous chorioretinopathy (Phase 2/3) has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Serous Chorioretinopathy

Drugs mentioned

• Bevacizumab (Avastin) (bevacizumab)

Snippet

Sponsor: Asociación para Evitar la Ceguera en México | Conditions: Central Serous Chorioretinopathy | Phase 2, Phase 3 | Status: WITHDRAWN